Analysis of current approaches and tools for cardiovascular risk assessing in young and middle-aged adults
O.I. Boeva, V.D. Oleinikova, V.N. Larina, D.N. Petrova
ABSTRACT. Early, adequate cardiovascular risk stratification as part of primary prevention is most justified in young and middle-aged individuals due to its maximum clinical benefits. An analysis of the main actual risk assessment tools designed to identify and correct cardiovascular risk factors in the 20–59 age group is performed. The majority of existing risk assessment systems are most effective within the population groups for which they were developed; their informativeness decreases when used in other populations, even after calibration based on current morbidity and mortality rates. Furthermore, significant differences can be observed in the structure and predictive value of cardiovascular risk factors in age cohorts under and over 40 years. Despite the potential of artificial intelligence and machine learning to improve the accuracy of risk stratification for any age group, the widespread implementation of these methods is limited by the lack of sufficient evidence of their clinical superiority over traditional approaches to personalized prognosis in primary prevention. A solution to this problem may lie in validating existing risk stratification models for target patient groups, as well as increasing their informativeness by expanding the set or varying the range of cardiovascular risk markers. It is also important to consider the availability of assessment methods in clinical practice, particularly in primary healthcare.
For citation: Boeva OI, Oleynikova VD, Larina VN, Rzhevskaya EV, Petrova DN, Baibuldin IR. Analysis of the current approach and tools for cardiovascular risk assessing in young and middle-aged adults. Therapy (Moscow). 2026;12(5S):75–85.
https://dx.doi.org/10.18565/therapy.2026.5-s5.75-85
Ключевые слова
cardiovascular risk stratification
risk measurement tools
young and middle-aged adult individuals
Russian population
Список литературы
1. Lukyanov MM, Andreenko EYu, Smirnov AA, Kudryavtseva MM, Kuzina NN, Klyashtorny VG, et al. [Outpatient-polyclinic register of the multidisciplinary medical center (TERRA): General characteristics and first results. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2023;22(6):35–45 (In Russ.)].
EDN: JBGLFL. https://doi.org/10.15829/1728-8800-2023-3598
2. Khan SS, Pencina MJ. Cardiovascular disease risk prediction in young adults – the next frontier. JAMA Сardiol.2023;8(2):137–38.
PMID: 36576809. https://doi.org/10.1001/jamacardio.2022.4887
3. Sun J, Qiao Y, Zhao M, Magnussen CG, Xi B. Global, regional, and national burden of cardiovascular diseases in youths and young adults aged 15–39 years in 204 countries/territories, 1990–2019: A systematic analysis of Global Burden of Disease Study 2019. BMC Med. 2023;21(1):222.
PMID: 37365627. PMCID: PMC10294522. https://doi.org/10.1186/s12916-023-02925-4
4. Daviglus ML, Stamler J, Pirzada A, Yan LL, Garside DB, Liu K, et al. Favorable cardiovascular risk profile in young women and long-term risk of cardiovascular and all-cause mortality. JAMA. 2004;292(13):1588–92.
PMID: 15467061. https://doi.org/10.1001/jama.292.13.1588
5. Rozanski A, Bavishi C, Kubzansky LD, Cohen R. Association of optimism with cardiovascular events and all-cause mortality: A systematic review and meta-analysis. JAMA Netw Open. 2019;2(9):e1912200.
PMID: 31560385. PMCID: PMC6777240. https://doi.org/10.1001/jamanetworkopen.2019.12200
6. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, Wilson PW. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290(7):891–97.
PMID: 12928465. https://doi.org/10.1001/jama.290.7.891
7. Patel R, Barnard S, Thompson K, Lagord C, Clegg E, Worrall R, et al. Evaluation of the uptake and delivery of the NHS Health Check programme in England, using primary care data from 9.5 million people: A cross-sectional study. BMJ Open. 2020;10(11): e042963.
PMID: 33154064. PMCID: PMC7646358. https://doi.org/10.1136/bmjopen-2020-042963
8. Lloyd-Jones DM, Braun LT, Ndumele CE, Smith SC Jr, Sperling LS, Virani SS, Blumenthal RS. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: A special report from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2019;73(24):3153–67.
PMID: 30423392. https://doi.org/10.1016/J.JACC.2018.11.005. Erratum in: J Am Coll Cardiol. 2019;73(24):3234.
https://doi.org/10.1016/j.jacc.2019.05.010.
9. Zaman S, Wasfy JH, Kapil V, Ziaeian B, Parsonage WA, Sriswasdi S, et al. The Lancet Commission on rethinking coronary artery disease: Moving from ischaemia to atheroma. Lancet. 2025;405(10486):1264–312.
PMID: 40179933. PMCID: PMC12315672. https://doi.org/10.1016/S0140-6736(25)00055-8
10. Thompson C. Rose’s prevention paradox. Journal of Applied Philosophy. 2018;35(2):242–56.
https://doi.org/10.1111/japp.12177
11. Boytsov SA, Drapkina OM. [Modern content and improvement of high cardiovascular risk strategy in reducing mortality from cardiovascular diseases. Terapevticheskiy arkhiv = Therapeutic Archive. 2021;93(1):4–6 (In Russ.)].
EDN: TBEVUH. https://doi.org/10.26442/00403660.2021.01.200543
12. Krogsboll LT, Jorgensen KJ, Gotzsche PC. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database Syst Rev. 2019;1(1):CD009009.
PMID: 30699470. PMCID: PMC6353639. https://doi.org/10.1002/14651858.CD009009.pub3
13. [Order of the Ministry of Health of the Russian Federation dated April 27, 2021 N 404n (as amended on July 19, 2024) “On approval of the procedure for conducting preventive medical examination and clinical examination of certain groups of the adult population” (Registered with the Ministry of Justice of Russia on June 30, 2021 N 64042). URL: https://base.garant.ru/401414440 (accessed May 24, 2026) (In Russ.)].
14. Boytsov SA, Pogosova NV, Ansheles AA, Badtieva VA, Balakhonova TV, Barbarash OL, et al. [Cardiovascular prevention 2022. Russian national guidelines. Rossiyskii kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2023;28(5):119–249 (In Russ.)].
EDN: EUDWYG. https://doi.org/10.15829/1560-4071-2023-5452
15. Arnold N, Koenig W. Polygenic risk score: Clinically useful tool for prediction of cardiovascular disease and benefit from lipid-lowering therapy? Cardiovasc. Drugs Ther. 2021;35(3):627–35.
PMID: 33156471. PMCID: PMC8481165. https://doi.org/10.1007/s10557-020-07105-7. Erratum in: Cardiovasc Drugs Ther. 2024;38(5):1069. https://doi.org/10.1007/s10557-021-07269-w
16. Albus C, Waller C, Fritzsche K, Gunold H, Haass M, Hamann B, et al. Significance of psychosocial factors in cardiology: Update 2018: Position paper of the German Cardiac Society. Clin Res Cardiol. 2019;108(11):1175–96.
PMID: 31076853. https://doi.org/10.1007/s00392-019-01488-w
17. Lee LO, James P, Zevon ES, Kim ES, Trudel-Fitzgerald C, Spiro A 3rd, et al. Optimism is associated with exceptional longevity in 2 epidemiologic cohorts of men and women. Proc Natl Acad Sci U S A. 2019;116(37):18357–62.
PMID: 31451635. PMCID: PMC6744861. https://doi.org/10.1073/pnas.1900712116
18. Tahir UA, Gerszten RE. Molecular biomarkers for cardiometabolic disease: Risk assessment in young individuals. Circ Res. 2023;132(12):1663–73.
PMID: 37289904. PMCID: PMC10320574. https://doi.org/10.1161/CIRCRESAHA.123.322000
19. Stone NJ, Smith SC Jr, Orringer CE, Rigotti NA, Navar AM, Khan SS, et al. Managing atherosclerotic cardiovascular risk in young adults: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79(8):819–36.
PMID: 35210038. https://doi.org/10.1016/j.jacc.2021.12.016
20. Lin JS, Evans CV, Johnson E, Redmond N, Coppola EL, Smith N. Nontraditional risk factors in cardiovascular disease risk assessment: Updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;320(3):281–97.
PMID: 29998301. https://doi.org/10.1001/jama.2018.4242
21. Post WS, Watson KE, Hansen S, Folsom AR, Szklo M, Shea S, et al. Racial and ethnic differences in all-cause and cardiovascular disease mortality: The MESA study. Circulation. 2022;146(3):229–39.
PMID: 35861763. PMCID: PMC9937428. https://doi.org/10.1161/CIRCULATIONAHA.122.059174
22. Anderson TS, Wilson LM, Sussman JB. Atherosclerotic cardiovascular disease risk estimates using the predicting risk of cardiovascular disease events equations. JAMA Intern Med. 2024;184(8):963–70.
PMID: 38856978. PMCID: PMC11165411. https://doi.org/10.1001/jamainternmed.2024.1302
23. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: Prospective open cohort study. BMJ. 2007;335(7611):136.
PMID: 17615182. PMCID: PMC1925200. https://doi.org/10.1136/bmj.39261.471806.55
24. Bruneau J, Parsons K, Moralejo D, Donovan C. Development of the Cardiovascular Assessment Screening Program (CASP) using the qualitative findings of a mixed methods study and applying the TDF to address the barriers of and facilitators to comprehensive screening for cardiovascular disease. BMC Prim Care. 2023;24(1):65.
PMID: 36882713. PMCID: PMC9990229. https://doi.org/10.1186/s12875-023-02022-8
25. Felix-Redondo FJ, Grau M, Baena-Díez JM, Degano IR, de Leon AC, Guembe MJ, et al. Prevalence of obesity and associated cardiovascular risk: the DARIOS study. BMC Public Health. 2013;(13):54.
PMID: 23738609. PMCID: PMC3695785. https://doi.org/10.1186/1471-2458-13-542
26. Jdanov DA, Deev AD, Jasilionis D, Shalnova SA, Shkolnikova MA, Shkolnikov VM. Recalibration of the SCORE risk chart for the Russian population. Eur J Epidemiol. 2014;29(9):621–28.
PMID: 25179794. PMCID: PMC4691263. https://doi.org/10.1007/s10654-014-9947-7
27. Graham IM, Di Angelantonio E, Visseren F, De Bacquer D, Ference BA, Timmis A, et al; European Society of Cardiology Cardiovascular Risk Collaboration. Systematic Coronary Risk Evaluation (SCORE): JACC Focus Seminar 4/8. J Am Coll Cardiol. 2021;77(24):3046–57.
PMID: 34140109. https://doi.org/10.1016/j.jacc.2021.04.052
28. Chipayo-Gonzales D, Ramakrishna H, Nunez-Gil IJ. Score2: A new updated algorithm to predict cardiovascular disease risk in Europe. J Cardiothorac Vasc Anesth. 2022;36(1):18–21.
PMID: 34686439. https://doi.org/10.1053/j.jvca.2021.09.033
29. Ezhov MV, Kukharchuk VV, Sergienko IV, Alieva AS, Antsiferov MB, Ansheles AA, et al. [Disorders of lipid metabolism. Clinical guidelines 2023. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2023;28(5):250–97 (In Russ.)].
EDN: YVZOWJ. https://doi.org/10.15829/1560-4071-2023-5471
30. [Order of the Ministry of Health of the Russian Federation dated July 19, 2024 No. 378n “On amendments to the procedure for conducting preventive medical examination and clinical examination of certain groups of the adult population, approved by Order of the Ministry of Health of the Russian Federation dated April 27, 2021 No. 404n”. URL: http://publication.pravo.gov.ru/document/0001202408190010 (accessed May 24, 2026) (In Russ.)].
31. [Decree of the Government of the Russian Federation dated December 29, 2025 No. 2188 “On the Program of state guarantees of free medical care to citizens for 2026 and for the planning period of 2027 and 2028” (as amended by Decree of the Government of the Russian Federation dated April 2, 2026 No. 365). URL: http://government.ru/docs/all/163114 (accessed May 24, 2026) (In Russ.)].
32. Svinin GE, Kutsenko VA, Shalnova SA, Yarovaya EB, Imaeva AE, Balanova YA, et al. Validation of SCORE2 on a sample from the Russian population and adaptation for the very high cardiovascular disease risk region. PLoS One. 2024;19(4):e0300974.
PMID: 38630773. PMCID: PMC11023576. https://doi.org/10.1371/journal.pone.0300974
33. Zairova AR, Rogoza AN, Oshchepkova EV, Shalnova SA, Trubacheva IA, Kaveshnikov VS, Boytsov SA. [SCORE2 cardiovascular risk stratification of an urban adult population sample and evaluation of its effectiveness based on 5-year follow-up. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2025;24(1):65–75 (In Russ.)].
EDN: HDBZAP. https://doi.org/10.15829/1728-8800-2025-4184
34. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk: A review for clinicians. J Am Coll Cardiol. 2009;54(14):1209–27.
PMID: 19778661. https://doi.org/10.1016/j.jacc.2009.07.020
35. [Draft clinical guidelines “Disorders of lipid metabolism”. 09.04.2026. URL: https://scardio.ru/news/novosti_obschestva/proekt_klinicheskih_rekomendaciy_narusheniya_lipidnogo_obmena (accessed May 24, 2026) (In Russ.)].
36. Berman AN, Biery DW, Besser SA, Singh A, Shiyovich A, Weber BN, et al. Lipoprotein(a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2024;83(9):873–86.
PMID: 38418000. PMCID: PMC12161880. https://doi.org/10.1016/j.jacc.2023.12.031
37. Gallo A, Charriere S., Vimont A, Vimont A, Alonso R, Muniz-Grijalvo O, et al; REFERCHOL and SAFEHEART Investigators. The added value of coronary calcium score in predicting cardiovascular events in familial hypercholesterolemia. JACC Cardiovasc Imaging. 2021;14(12):2414–24.
PMID: 34274263. https://doi.org/10.1016/j.jcmg.2021.06.011
38. [Register of Medicines of Russia. Framingham-30 calculator. URL: https://www.rlsnet.ru/med-calculators/kardiologiya/framingemskaya-skala-serdecno-sosudistogo-riska-66 (accessed May 24, 2026) (In Russ.)].
39. Pencina MJ, D’Agostino RB Sr, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: The Framingham heart study. Circulation. 2009;119(24):3078–84. PMID: 19506114. PMCID: PMC2748236.
https://doi.org/10.1161/CIRCULATIONAHA.108.816694
40. Berger JS, Jordan CO, Lloyd-Jones D, Blumenthal RS. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol. 2010;55(12):1169–77.
PMID: 20298922. https://doi.org/10.1016/j.jacc.2009.09.066
41. Rospleszcz S, Starnecker F, Linkohr B, von Scheidt M, Gieger C, Schunkert H, Peters A; DigiMed Bayern Consortium. Validation of the 30-year Framingham risk score in a German population-based cohort. Diagnostics (Basel). 2022;12(4):965.
PMID: 35454012. PMCID: PMC9025787. https://doi.org/10.3390/diagnostics12040965
42. Bhuiyan A, Govindaiah A, Smith RT. External validation of four cardiovascular risk prediction models. J Clin Cardiol. 2024;5(2):73–80.
https://doi.org/10.33696/cardiology.5.057
43. Chia YC, Gray SY, Ching SM, Lim HM, Chinna K. Validation of the Framingham general cardiovascular risk score in a multiethnic Asian population: A retrospective cohort study. BMJ Open. 2015;5(5):e007324.
PMID: 25991451. PMCID: PMC4442208. https://doi.org/10.1136/bmjopen-2014-007324
44. Trzeciak BG, Siebert J, Gutknecht P, Molisz A, Filipiak KJ, Wozakowska-Kapłon B. Cardiovascular risk factors determined via the Internet in 2 periods of time: 2004–2009 and 2010–2015 in Poland. Int J Occup Med Environ Health. 2017;30(3):499–510.
PMID: 28481381. https://doi.org/10.13075/ijomeh.1896.00835
45. Wessler BS, Nelson J, Park JG, McGinnes H, Gulati G, Brazil R, et al. External validations of cardiovascular clinical prediction models: A large-scale review of the literature. Circ Cardiovasc Qual Outcomes. 2021;14(8):e007858.
PMID: 34340529. PMCID: PMC8366535. https://doi.org/10.1161/CIRCOUTCOMES.121.007858
46. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: Prospective cohort study. BMJ. 2017;357:j2099.
PMID: 28536104. PMCID: PMC5441081. https://doi.org/10.1136/bmj.j2099
47. Parsons RE, Liu X, Collister JA, Clifton DA, Cairns BJ, Clifton L. Independent external validation of the QRISK3 cardiovascular disease risk prediction model using UK Biobank. Heart. 2023;109(22):1690–97.
PMID: 37423742. PMCID: PMC10646868. https://doi.org/10.1136/heartjnl-2022-321231
48. Vasilenko EA, Gaidukova IZ, Samigullina RR, Dadalova AM, Mazurov VI. [Cardiovascular risk factors in patients with axial spondyloarthritis. Terapiya = Therapy. 2019;5(8):81–88 (In Russ.)].
EDN: SOOAII. https://doi.org/10.18565/therapy.2019.8.81-88
49. Woodward M, Brindle P, Tunstall-Pedoe H; SIGN group on risk estimation. Adding social deprivation and family history to cardiovascular risk assessment: The ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart. 2007;93(2):172–76.
PMID: 17090561. PMCID: PMC1861393. https://doi.org/10.1136/hrt.2006.108167
50. ASSIGN score website. URL: http://assign-score.com/ (accessed May 24, 2026).
51. Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, et al.; Chronic Kidney Disease Prognosis Consortium and the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group. Development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024;149(6):430–49.
PMID: 37947085. PMCID: PMC10910659. https://doi.org/10.1161/CIRCULATIONAHA.123.067626. Erratum in: Circulation. 2024;149(11):e956. https://doi.org/10.1161/CIR.0000000000001230
52. Mora S, Wenger NK, Cook NR, Liu J, Howard BV, Limacher MC, et al. Evaluation of the pooled cohort risk equations for cardiovascular risk prediction in a multiethnic cohort from the Women’s Health Initiative. JAMA Intern Med. 2018;178(9):1231–40.
PMID: 30039172. PMCID: PMC6142964. https://doi.org/10.1001/jamainternmed.2018.2875
53. Vassy JL, Lu B, Ho YL, Galloway A, Raghavan S, Honerlaw J, et al. Estimation of atherosclerotic cardiovascular disease risk among patients in the Veterans Affairs Health Care System. JAMA Netw Open. 2020;3(7):e208236.
PMID: 32662843. PMCID: PMC7361654. https://doi.org/10.1001/jamanetworkopen.2020.8236
54. Anderson TS, Wilson LM, Sussman JB. Atherosclerotic cardiovascular disease risk estimates using the predicting risk of cardiovascular disease events equations. JAMA Intern Med. 2024;184(8):963–70.
PMID: 38856978. PMCID: PMC11165411. https://doi.org/10.1001/jamainternmed.2024.1302
55. Diao JA, Shi I, Murthy VL, Buckley TA, Patel CJ, Pierson E, et al. Projected changes in statin and antihypertensive therapy eligibility with the AHA PREVENT cardiovascular risk equations. JAMA. 2024;332(12):989–1000.
PMID: 39073797. PMCID: PMC11287447. https://doi.org/10.1001/jama.2024.12537
56. Bakulin GG, Serezhina EK, Obrezan AG. Features of assessment of cardiovascular risk using SCORE, SCORE2 and PREVENT scales in patients with atherosclerosis-associated cardiovascular pathology. Kardiologiya: novosti, mneniya, obuchenie = Cardiology: News, Opinions, Education. 2026;14(1):16–23 (In Russ.)].
EDN: GWVRVZ. https://doi.org/10.33029/2309-1908-2026-14-1-16-23
57. Drapkina OM, Shalnova SA, Balanova YuA, Kutsenko VA, Imaeva AE, Kapustina AV, et al. [The Russian prognostic scale “PHOENIX” – a novel domestic tool for cardiovascular risk assessment. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2025;24(9):7–19 (In Russ.)].
EDN: VRSPIN. https://doi.org/10.15829/1728-8800-2025-4510
58. Boytsov SA, Drapkina OM, Shlyakhto EV, Konradi AO, Balanova YuA, Zhernakova YuV, et al. [Epidemiology of cardiovascular diseases and their risk factors in regions of Russian Federation (ESSE-RF) study. Ten years later. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2021;20(5):143–52 (In Russ.)].
EDN: ZPGROP. https://doi.org/10.15829/1728-8800-2021-3007
59. Filippov EV, Vorobyev AN, Dobrynina NV, Zotova LA, Lygina EV, Nikulina NN, еt al. [Adverse cardiovascular outcomes and their relationship with risk factors according to the prospective study MERIDIAN-RO. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2019;24(6):42–48 (In Russ.)].
EDN: ZYBYEX. https://doi.org/10.15829/1560-4071-2019-6-42-48
60. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: New models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):243954.
PMID: 34120177. PMCID: PMC8248998. https://doi.org/10.1093/eurheartj/ehab309
61. Shvets DA, Povetkin SV. [Comparative review of the use of machine learning methods for predicting cardiovascular risk. Vestnik novykh meditsinskikh tekhnologiy = Journal of New Medical Technologies. 2020;(5):74–82 (In Russ.)].
EDN: LMFMWX. https://doi.org/10.24411/2075-4094-2020-16711
62. Sanchez-Martinez S, Camara O, Piella G, Cikes M, Gonzalez-Ballester MA, et al. Machine learning for clinical decision-making: Challenges and opportunities in cardiovascular imaging. Front Cardiovasc Med. 2022;8:765693.
PMID: 35059445. PMCID: PMC8764455. https://doi.org/10.3389/fcvm.2021.765693
63. Khazova EV, Shulaeva PA, Savzikhanova RR, Malkova MI. Integration of artificial intelligence technologies in electrocardiogram analysis: Current trends and prospects. A review. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2026;31(S2):154–61 (In Russ.)].
EDN: VRWPXX. https://doi.org/10.15829/1560-4071-2026-6835
64. Rosenberg MA. Trusting magic: Interpretability of predictions from machine learning algorithms. Circulation. 2021;143(13):1299–301.
PMID: 33779269. PMCID: PMC8010916. https://doi.org/10.1161/CIRCULATIONAHA.121.053733
65. Chashchin MG, Yurin AV, Strelkova AV, Gorshkov AYu, Drapkina OM. [Problems and solutions in applying machine learning algorithms for data analysis in cardiology. Profilakticheskaya meditsina = The Russian Journal of Preventive Medicine. 2025;28(10):16–22 (In Russ.)].
EDN: QJQFMQ. https://doi.org/10.17116/profmed20252810116
66. Kaveshnikov VS, Bragin DS, Vaizov VKh, Kaveshnikov AV, Kuzmichkina MA, Trubacheva IA. [Possibilities of applying machine learning technologies in the sphere of primary prevention of cardiovascular diseases. Kompleksnye problemy serdechno-sosudistykh zabolevanii = Complex Issues of Cardiovascular Diseases. 2023;12(3):109–25 (In Russ.)].
EDN: WICLRX. https://doi.org/10.17802/2306-1278-2023-12-3-109-125
Об авторах / Для корреспонденции
Olga I. Boeva, MD, Dr. Sci. (Medicine), professor, professor of the Department of outpatient therapy of the Institute of clinical medicine, Pirogov Russian National Research Medical University; scientific consultant and therapist at Polyclinic No. 1 of the Administrative Department of the President of the Russian Federation, Moscow, Russian Federation.E-mail: box0271@mail.ru
ORCID: https://orcid.org/0000-0002-1816-8309. Scopus ID: 57208068531
Victoria D. Oleynikova, MD, clinical resident of the Department of outpatient therapy of the Institute of clinical medicine, Pirogov Russian National Research Medical University, Moscow, Russian Federation.
E-mail: victoria-ol@mail.ru
ORCID: https://orcid.org/0000-0002-1304-6046. Scopus ID: 57926616800
Vera N. Larina, MD, Dr. Sci. (Medicine), professor, head of the Department of outpatient therapy, Institute of clinical medicine, Pirogov Russian National Research Medical University; scientific consultant, therapist at Polyclinic No. 1 of the Administrative Department of the President of the Russian Federation, Moscow, Russian Federation.
E-mail: larinav@mail.ru
ORCID: https://orcid.org/0000-0001-7825-5597. Scopus ID: 36850407300
Elena V. Rzhevskaya, MD, chief physician at Polyclinic No. 1 of the Administrative Department of the President of the Russian Federation, Moscow, Russian Federation.
E-mail: e.rzhevskaya@vipmed.ru
ORCID: https://orcid.org/0009-0006-2534-0118. Scopus ID: 57224909367
Darina N. Petrova, MD, head of the therapy department No. 3, Polyclinic No. 1 of the Administrative Department of the President of the Russian Federation, Moscow, Russian Federation.
E-mail: d.petrova@vipmed.ru
ORCID: https://orcid.org/0009-0002-0422-2367.
Ilnaz R. Baibuldin, MD, therapist of Home Care Department, Polyclinic No. 1 of the Administrative Department of the President of the Russian Federation, Moscow, Russian Federation.
E-mail: i.baibuldin@vipmed.ru
ORCID: https://orcid.org/0009-0007-2099-2608
Natalia E. Koretskaya, Head of the Outpatient Medical Rehabilitation Department , Polyclinic No. 1 of the Administrative Department of the President of the Russian Federation, Moscow, Russian Federation.
E-mail: n.koretskaya@vipmed.ru
https://orcid.org/0009-0008-3217-3578
